Welcome to our dedicated page for Atai Beckley SEC filings (Ticker: ATAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AtaiBeckley Inc. filings document a clinical-stage biotechnology issuer with Nasdaq-listed common shares and psychiatry-focused investigational drug programs. The company’s regulatory record includes proxy and governance disclosures, shareholder voting matters, operating and financial results, clinical and regulatory updates, and risk-related information tied to development programs such as BPL-003, VLS-01, and EMP-01.
Material-event filings and registration-related documents also cover capital-structure activity, public offering agreements, resale registration matters, and acquisition-related share registration connected with Beckley Psytech. Historical filings under ATAI Life Sciences N.V. and Atai Beckley N.V. provide reference for the company’s corporate transition, financing activity, governance framework, and formal disclosure of business updates.
Apeiron Investment Group Ltd., affiliated funds and individuals, including Christian Angermayer, amend their Schedule 13D for AtaiBeckley Inc. following a July 15, 2026 Agreement and Plan of Merger among AtaiBeckley, Eli Lilly and Company and Albali Acquisition Corporation.
As of June 22, 2026, the reporting persons collectively beneficially own 56,812,134 shares of AtaiBeckley common stock, representing 15.4% of voting rights, based on 368,166,674 shares outstanding. Apeiron and Angermayer have entered into Voting and Support Agreements to vote all their shares in favor of adopting the Merger Agreement and to refrain from transferring such shares, subject to specified exceptions.
AtaiBeckley Inc. agreed to be acquired by Eli Lilly and Company via a merger under which each AtaiBeckley share will receive $6.75 in cash at closing plus one non-transferable contingent value right (CVR) for up to an additional $2.50 in cash per share.
Each CVR pays cash only if milestones are met: up to $1.00 per share for initiation of a Phase 3 trial of VLS-01 within four years of closing, $0.50 for U.S. approval and DEA rescheduling of BPL-003 within five years, and $1.00 for U.S. approval and rescheduling of VLS-01 within seven years.
The upfront price values AtaiBeckley at about $2.8 billion, with CVRs adding up to $1.0 billion more, representing roughly a 40% premium to the 30-day VWAP. Closing, targeted for the third quarter, is subject to stockholder and regulatory approvals and other conditions; a $104.3 million termination fee and voting agreements covering about 15% of shares are included in the deal terms.
AtaiBeckley Inc. director Robert Hershberg reported option exercises and share sales. On July 7, 2026, he exercised stock options to acquire 100,000 shares of common stock at $1.35 per share and sold 100,000 shares at a weighted average price of $4.96.
The sales occurred in multiple trades between $4.90 and $5.08 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly held 100,000 shares of AtaiBeckley common stock.
AtaiBeckley Inc.’s Chief Medical Officer, Craig Kevin James, reported an option exercise-and-sale transaction in company stock. On June 25, 2026, he exercised stock options covering 42,579 shares of common stock at strike prices of $1.18 and $1.50 per share and sold 42,579 shares in open-market transactions at a weighted average price of $4.51 per share. The filing states these option exercises and sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 19, 2025. After the transactions, he held 8,437 shares of common stock directly and continued to hold stock options, including 28,608 options at an exercise price of $1.18 expiring on March 14, 2033 and 673,808 options at an exercise price of $1.50 expiring on March 3, 2035.
AtaiBeckley Inc. Chief Operating Officer Gerd Kochendoerfer reported an options exercise and share sale involving the company’s common stock. On June 26, 2026, he sold 50,000 shares in an open-market transaction at $5.00 per share and exercised stock options to acquire 50,000 shares at $1.60 per share.
The filing indicates these option exercises and related sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2026, which means the trades were scheduled in advance. Following the transactions, Kochendoerfer directly holds 50,000 common shares and 1,400,000 stock options that remain outstanding, according to the reported post-transaction balances.
The issuer submitted a Form 144 disclosing an intended sale related to an exercise of stock options on 06/25/2026 covering 85,158 shares of common stock to be sold for cash. The filing also records prior 10b5-1 sales by Kevin James Craig of 42,579 shares on 04/20/2026 for $212,895.
AtaiBeckley Inc. director and 10% owner Christian Angermayer received a grant of stock options covering 121,968 shares of common stock at an exercise price of $4.50 per share. These options expire on June 4, 2036.
The options will vest on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, provided Angermayer continues to serve on the company's board of directors through the applicable vesting date. Following this grant, his reported option holdings from this award total 121,968 shares.
AtaiBeckley Inc. director Scott Braunstein received two stock option awards. On June 4, 2026, he was granted options covering 86,095 and 121,968 shares of common stock at an exercise price of $4.50 per share, expiring on June 4, 2036.
The options were granted as compensation and not through open-market purchases. According to the footnote, each option will vest on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, provided he continues to serve on the board through the vesting date.